Document:

Exhibit 10.37

SUPPLEMENTAL CONFIRMATION

				
	To:

    

    			Aspen Insurance Holdings Limited

 Maxwell Roberts Building

1 Church Street

Hamilton, HM 11

Bermuda
	From:			Goldman, Sachs & Co.
	Subject:			Collared Accelerated Stock Buyback
	Ref. No:			[Insert Reference No.]
	Date:			November 9, 2007

	
		
	

The purpose of this Supplemental Confirmation is to confirm the terms and conditions of the Transaction entered into between Goldman, Sachs & Co. (‘‘GS&Co.’’) and Aspen Insurance Holdings Limited (‘‘Counterparty’’) (together, the ‘‘Contracting Parties’’) on the Trade Date specified below. This Supplemental Confirmation is a binding contract between GS&Co. and Counterparty as of the relevant Trade Date for the Transaction referenced below.

1.         This Supplemental Confirmation supplements, forms part of, and is subject to the Master Confirmation dated as of September 28, 2007 (the ‘‘Master Confirmation’’) between the Contracting Parties, as amended and supplemented from time to time. All provisions contained in the Master Confirmation govern this Supplemental Confirmation except as expressly modified below.

2.         The terms of the Transaction to which this Supplemental Confirmation relates are as follows:

				
	Trade Date:			November 9, 2007
	Forward Price Adjustment Amount:			USD [***]
	Hedge Completion Date:			As set forth in the Trade Notification, but in no event later than November 30, 2007
	Scheduled Termination Date:			[***] after the Calculation Period Start Date (or, if such date is not a Scheduled Trading Day, the next following Scheduled Trading Day), subject to GS&Co.’s right to accelerate the Termination Date to any date on or after the First Acceleration Date.
	First Acceleration Date:			[***] after the Calculation Period Start Date (or, if such date is not a Scheduled Trading Day, the next following Scheduled Trading Day).

	
		
	

*** indicates material has been omitted pursuant to a Confidential Treatment Request filed with the Securities and Exchange Commission. A complete copy of this agreement has been filed separately with the Securities and Exchange Commission.

1

				
	Calculation Period:			Notwithstanding the Master Confirmation, the Calculation Period shall begin on and include the first Exchange Business Day (such date, the ‘‘Calculation Period Start Date’’) immediately following the latest of (i) the Scheduled Termination Date under the First 2007 ASB Transaction, (ii) the last day of the Settlement Valuation Period, if any, under the First 2007 ASB Transaction, and (iii) the date all sales of Shares (or other securities) contemplated by Annex A to the Master Confirmation with respect to the First 2007 ASB Transaction, if any, have been completed.
	 			In the event of a Second Settlement occurring with respect to the First 2007 ASB Transaction after the Calculation Period Start Date, the Calculation Period shall not include any day in the period during which sales of Shares (or other securities) contemplated by Annex A to the Master Confirmation with respect to the First 2007 ASB Transaction, if any, occur (the ‘‘First 2007 ASB Second Settlement Period’’). Notwithstanding the Master Confirmation, the Scheduled Termination Date shall be postponed by a number of Exchange Business Days equal to the number of Exchange Business Days occurring during the First 2007 ASB Second Settlement Period.
	First 2007 ASB Transaction:			The Transaction (Ref. No: SDB1626308626) entered into between Counterparty and GS&Co. with a Trade Date of September 28, 2007.
	Prepayment Amount:			USD 50,000,000
	Counterparty Additional Payment Amount:			USD 0
	Minimum Shares:			As set forth in the Trade Notification, to be a number of Shares equal to (a) the Prepayment Amount divided by (b) [***]% of the Hedge Period Reference Price.
	Maximum Shares:			As set for in the Trade Notification, to be a number of Shares equal to (a) the Prepayment Amount divided by (b) [***]% of the Hedge Period Reference Price.
	Ordinary Dividend Amount:			For any calendar quarter, USD 0.15
	Reserved Shares:			2,500,000

3.         This Supplemental Confirmation may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Supplemental Confirmation by signing and delivering one or more counterparts.

	
		
	

*** indicates material has been omitted pursuant to a Confidential Treatment Request filed with the Securities and Exchange Commission. A complete copy of this agreement has been filed separately with the Securities and Exchange Commission.

2

Counterparty hereby agrees (a) to check this Supplemental Confirmation carefully and immediately upon receipt so that errors or discrepancies can be promptly identified and rectified and (b) to confirm that the foregoing (in the exact form provided by GS&Co.) correctly sets forth the terms of the agreement between GS&Co. and Counterparty with respect to this Transaction, by manually signing this Supplemental Confirmation or this page hereof as evidence of agreement to such terms and providing the other information requested herein and immediately returning an executed copy to Equity Derivatives Documentation Department, facsimile No. 212-428-1980/83.

		Yours sincerely,

		GOLDMAN, SACHS & CO.

     

    

By:/s/ Debra Tageldein                                    

Authorized Signatory

        

Agreed and accepted by:

ASPEN INSURANCE HOLDINGS LIMITED

    

By:/s/ Richard Houghton            

       Name: Richard Houghton

       Title: Chief Financial Officer

	
		
	

*** indicates material has been omitted pursuant to a Confidential Treatment Request filed with the Securities and Exchange Commission. A complete copy of this agreement has been filed separately with the Securities and Exchange Commission.

3Exhibit 10.38

LETTER AGREEMENT

This Letter Agreement (this ‘‘Letter Agreement’’) is made as of November 9, 2007, between Goldman, Sachs & Co. (‘‘GS&Co.’’) and Aspen Insurance Holdings Limited (‘‘Counterparty’’).

WHEREAS, GS&Co. and Counterparty are parties to the Master Confirmation, dated September 28, 2007, containing terms relating to accelerated stock buyback transactions to be entered by GS&Co. and Counterparty (the ‘‘Master Confirmation’’);

WHEREAS, GS&Co. and Counterparty entered into a Transaction under the Master Confirmation evidenced by a Supplemental Confirmation to the Master Confirmation dated September 28, 2007 (reference number SDB 1626308626) (the ‘‘First 2007 ASB Transaction’’);

WHEREAS, GS&Co. and Counterparty entered into a Transaction under the Master Confirmation evidenced by a Supplemental Confirmation to the Master Confirmation dated November 9, 2007 (reference number [        ]) (the ‘‘Second 2007 ASB Transaction’’);

NOW, THEREFORE, in consideration of their mutual covenants herein contained, GS&Co. and Counterparty agree as follows:

Section 1. Terms Used but Not Defined Herein. Capitalized terms used but not defined herein shall have the meanings set forth in the Master Confirmation.

Section 2. Representations, Warranties and Covenants of Counterparty. Counterparty represents and warrants to GS&Co. that it is not entering into this Letter Agreement on the basis of, and is not aware of, any material non-public information with respect to itself or the Shares.

Section 3. Amendments. The Master Confirmation is hereby amended by replacing Section 7(b) with the following: ‘‘(b) In respect of any Transaction, the parties agree that Section 4(k) and Section 7(a) shall not prohibit privately-negotiated, off-market repurchases by Counterparty (i) of Shares from Appleby Trust (Bermuda) Limited or any of its successors, and (ii) of restricted Share units from directors or former directors and their affiliates, in either case during the Hedge Period, Calculation Period or, if applicable, Settlement Valuation Period of such Transaction.’’

The First 2007 ASB Transaction is hereby amended so that the Calculation Period under the First 2007 ASB Transaction shall not include any day in the period from and including November 12, 2007 to and including the Hedge Completion Date under the Second 2007 ASB Transaction, and the Scheduled Termination Date shall be postponed by a number of Exchange Business Days equal to the number of Exchange Business Days occurring during such period. For the avoidance of doubt, the parties agree that the Second 2007 ASB Transaction does not violate Counterparty’s obligation under Section 4(k) or 7(a) of the Master Confirmation with respect to the First 2007 ASB Transaction.

Section 4. Governing Law. This Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York.

Section 5. Confirmation of Agreements. Except as amended hereby, the Master Confirmation and the First 2007 ASB Transaction shall each remain and continue in full force and effect and are hereby confirmed in all respects.

Section 6. Counterparts. This Letter Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if all of the signatures thereto and hereto were upon the same instrument.

2

IN WITNESS WHEREOF, the parties hereto have caused this Letter Agreement to be executed as of the date first above written.

		GOLDMAN, SACHS & CO.

     

    

By:/s/ Debra Tageldein                                    

        Authorized Signatory

        

		ASPEN INSURANCE HOLDINGS LIMITED

     

By:/s/ Richard Houghton                                

        Name: Richard Houghton

        Title: Chief Financial Officer

3MEMORANDUM OF UNDERSTANDING

     This  updated  Memorandum of Understanding (the "MOU") is made effective as
of  February  22,  2008  (the  "Effective Date"), by and among Stem Cell Therapy
International,  Inc.,  a  U.S. publicly traded corporation ("SCTI"), Calvin Cao,
Chairman  and CEO of SCTI, and Dr. Hoon Han, President and CEO of Histostem Co.,
Ltd.,  a  Korean  company ("Histostem") and together with Dr. Han and Histostem,
Mr.  Cao  and  SCTI  are  collectively referred to as the "Parties".

                                  Definitions

Following abbreviations shall be used to define their exact meaning in this MOU:

     a.   "SCTI"  shall  mean  the  Stem  Cell  Therapy  International,  Inc., a
          corporation  organized  under  the  laws  of  the State of Nevada, and
          having  its  principal  location  at  2203  N. Lois Avenue, 9th Floor,
          Tampa,  FL  33607, U.S.A. Mr. Calvin Cao is currently the Chairman and
          CEO  of  SCII.

     b.   "SCII"  shall  mean  the  stock/ticker  symbol  of  the  above  SCTI
          company  and  shall  be used as the same meaning with SCTI in this MOU

     c.   "Histostem"  shall  mean  the  Histostem  Co.,  Ltd.,  a  corporation
          organized  under  the  laws  of  the Republic of Korea, and having its
          principal  location  518-4  Seoul Life Foundation Bldg., Dunchon-Dong.
          Kangdong-Gu, Seoul, Korea, Dr. Han-Hoon is currently the President and
          CEO  of  Histostem.

     d.   "PUBCO"  means  a  new  Public  Company  name that will be selected by
          Histostem  at  the  close  of  the transaction that will represent the
          combined  companies  of  SCTI and Histostem and that will obtain a new
          stock  symbol.

     WHEREAS,  the  Parties desire to enter into a definitive Reorganization and
Stock Purchase agreement whereby SCTI will acquire 100% of the outstanding stock
of  Histostem  from  the  Histostem  Shareholders, in exchange for a controlling
interest  in SCTI, and at the time of closing adopt a new public company (PUBCO)
name;

     AND  WHEREAS,  the  Parties wish to memorialize the terms and conditions of
such  an  agreement;

     NOW, THEREFORE, in consideration of the foregoing, the mutual covenants and
agreements  contained  herein,  and  other  good and valuable consideration, the
receipt  and  sufficiency  of  which are hereby acknowledged, the parties hereto
agree  as  follows:

     1.  Definitive  Agreement.  A formal agreement (the "Definitive Agreement")
containing  the  terms  and  conditions memorialized herein will be prepared and
entered into within fifteen (15) days of the execution of this Agreement, unless
both  parties  agree  to  extend  the  date  by written consent. If a Definitive
Agreement cannot be reached within 60 days both parties agreed to cease actions,
and  terminate  this  MOU,  without  legal  recourse.

                                        1
<PAGE>
     2.  Terms  of the Agreement. The terms of the Definitive Agreement shall be
as  follows.  If  any  necessary  terms are not covered in this MOU they will be
determined during the upcoming meeting for the Definitive Agreement based on the
schedule  agreed  by  the  parties:

     The  Share  Transaction.  SCTI  will  exchange  a  controlling  interest in
     SCTI  for  100%  of the outstanding stock of Histostem (the "Transaction").
     Upon  the  closing of the transaction, Histostem will become a wholly owned
     subsidiary  of  SCTI  and  shall  continue  to  operate  in  Korea, and the
     Histostem  Shareholders  will  collectively  own  60% of the newly combined
     entity  at  the time of the completion of the merger and SCTI will own 40%.
     While it shall be legally domiciled as a U.S. public company, the principal
     place  of  operations  of the combined entity shall remain Seoul, Korea and
     SCTI  will  only maintain a branch office of such size and operations as is
     set forth in the Definitive Agreement in the United States. The persons who
     work  in  the  U.S.  office  and manage the business affairs of that office
     shall  be  selected  by  the  U.S.  Operations  of  the  new  entity..

     Escrow.  Within  15  business  days  after  entering  the  Definitive
     Agreement,  the parties will execute all documents as are required to close
     the  transaction,  issue all shares as are required, and deliver all shares
     and  documents into escrow with a mutually approved U.S. law firm to act as
     escrow  agent.

     Legal  Advisor  or  Counsel.  Both  parties  may  engage  a U.S. securities
     law  firm  to  act  as a legal advisor to each party as necessary and to be
     counsel  for  this  transaction;  each  party  to pay its own legal expense

     Financial  Statements.  On  or  before  March  30,  2008,  and  prior  to
     closing,  Histostem  will  provide  to  SCTI  completed  audited  financial
     statements  of  Histostem  in  accordance  with US GAAP, sufficient to file
     under  Regulation  S-X  with  the  United  States  Securities  and Exchange
     Commission  ("SEC").

     e.  Exchange  Listing  Status.  SCTI  warrants  that  SCTI  is  quoted  for
     trading  on  the  over  the  counter  bulletin board (OTC-BB) maintained by
     NASDAQ.  SCTI will warrant that PUBCO will be eligible to be listed on AMEX
     or  NASDAQ  provided that PUBCO as the combined entity with Histostem meets
     the  share  price,  net  tangible  assets  and  other requirements for such
     listing.  Provided that PUBCO (as the combined entity with Histostem) meets
     such  listing  requirements,  the  Parties  intend  to apply for listing on
     either  AMEX  or NASDAQ prior to the first round of funding, which is after
     the  initial  funding  period.

     f.  Periodic  Reports.  SCTI  will  warrant  that  it  is  current with its
     obligations to file periodic reports with the SEC. For a period of one year
     after  closing,  Mr.  Cao  will provide assistance to the new management of
     PUBCO  with regards to these SEC filing requirements. The combined entities
     will  engage  a  mutually  agreed upon U.S. securities law firm to serve as
     legal  counsel  to  PUBCO.

     g.  Directors of PUBCO.  At  the time of closing, the Board of Directors of

                                        2
<PAGE>
     PUBCO  will  have  five  members,  four  chosen by Histostem and one chosen
     by the current management of SCTI. The director to serve as Chairman of the
     Board  will  be  chosen  by  Histostem. Management of PUBCO. At the time of
     closing,  PUBCO  will  have  such  officers  and other employees as will be
     chosen  by  Histostem;  the  officers  and employees of the U.S. operations
     shall  be  selected  by SCTI. Name Change and Capital Increase. Immediately
     prior  to  closing,  the  authorized  capital  of  SCTI  will  be raised to
     500,000,000 shares of common stock in maximum, and SCTI will be re-named to
     a  new  name determined by Histostem in conjunction with consultations with
     SCTI, prior to execution of the Definitive Agreement. It is understood that
     under  SEC  regulations  the name change cannot be effective or used by the
     public  company  PUBCO  until  the  transaction  has  closed  and filed all
     necessary  paperwork  with  the  SEC.

     Fundraising.

          i. Fundraising Goal. The fundraising efforts will be undertaken by the
     new  combined  entity, and Investment Bankers on a best efforts basis, with
     the  objective  of  attempting  to  achieve  a  total  fund raising goal of
     $80,000,000.  The  parties acknowledge that the actual amount of funding in
     each  round  may  be affected by many factors outside of one or more of the
     Parties'  control, including the status of the audited financial statements
     of  the  combined  entity,  the  business  plan  accomplishments of the new
     entity,  and  changes  in  market  conditions.

          ii.  Best Efforts Basis. It is understood that the fundraising efforts
     to  be  undertaken  will  be  on  a  Best  Efforts  Basis,  as that term is
     understood  by U.S. investment bankers and public companies raising capital

          iii.  Source  of  Capital.  The  capital  required  for  operations by
     Histostem  shall  be  provided  from  newly  issued  stock  of  PUBCO.  Any
     additional  capital  raised after the first round, either through equity or
     through  any other security, regardless of how the capital is raised, shall
     be  disbursed  49%  to  the  US  operations  of PUBCO and 51% to the Korean
     operations  of  Histostem,  respectively.

          iv.  Initial  Round.  The  work for the initial round of the financing
     goal  shall  commence immediately upon the signing of this MOU and shall be
     paid as soon as the funds are available provided that at the time of paying
     the  funds  the  US GAAP prepared audited financial statements of Histostem
     are  completed  and  the Definitive Agreement is prepared and signed at the
     time of funding. The initial round of the financing goal will be undertaken
     by  SCTI and a broker-dealer it selects on a best efforts basis for a total
     of  up  to  $3.0M.  Of  this  amount,  $2.0M  will be used by Histostem for
     immediate operating capital, and $1.0M will be used by SCTI, according to a
     Use  of Proceeds statement that shall be submitted to SCTI, and approved by
     them,  within  fifteen  (15)  days  after  the  effective date of this MOU.

                                        3
<PAGE>
          v.  First  Round.  The first round of financing shall occur as soon as
     reasonably  possible but no later than six (6) months following the initial
     round  financing and will be undertaken by SCTI on a best efforts basis for
     a  total  of  up  to  $25,000,000.  Among  the  first  round  of financing,
     $15,000,000  will be used by Histostem (the Korean subsidiary of PUBCO) and
     the  remaining  $10,000,000  will be used by PUBCO for long term growth and
     operations  according  to a Use of Proceeds Statement to be approved by the
     Board  of  PUBCO

          vi.  Further  Rounds.  Other  financing  rounds  will occur, beginning
     within  twelve  (12)  months  following  the  second  round,  and  will  be
     undertaken on a best efforts basis for a overall total of up to $80,000,000
     including  proceeds  from the first two rounds. Proceeds from these further
     rounds  will  be  used  by  Histostem and SCTI (as the combined entity with
     Histostem)  for  long  term  growth  and  operations  according to a Use of
     Proceeds  statement  to  be  approved  by  the  Board  of  the  PUBCO.

          vii.  Distribution  of  Equity  After  the  completion  of the reverse
     merger, in consideration of 100% of the current Histostem shares, Histostem
     will  own 60% equity and SCTI will own 40% equity of the new public company
     (PUBCO).

          viii.  Limitations  on  Liability  for  Best  Efforts Financing. It is
     understood  that  the  ability  to obtain financing is dependent on several
     factors  that  are  out  of  the  control  of  Mr.  Cao and SCTI, including
     Histostem  successfully  implementing its business plan and meeting its pro
     forma financial milestones, and current market conditions. It is understood
     that Mr. Cao and SCTI shall incur no liability with respect to those events
     or  the  resulting  price  per  share.

     k.  Issuances  for  Services.  In  addition  to  the  shares  issued to the
     Histostem  Shareholders pursuant to the Definitive Agreement, at closing of
     the  reverse  merger  SCTI  will  issue  1,000,000  common  shares  each to
     Primebell  and  Princeton  Healthcare  for  services rendered to Histostem.
     Furthermore,  Mr.  Newman  and Mr. Calvin Cao will agree to provide ongoing
     services  to  PUBCO  for  a period of five (5) years and they shall each be
     paid  for such services according to the terms to be set forth and mutually
     agreed  to  in  the  Definitive Agreement. SCTI and not Histostem, shall be
     obligated  to  pay  for  the  merger  services  of Mr. Newman in making the
     introduction,  such  payment  to take place at or before the signing of the
     Definitive  Agreement.

     l.  Antidilution.  For  a  period  of twenty-four (24) months from the date
     of  the  first  round  of  financing,  the  Parties agree not to attempt or
     implement  any  reverse splits or other efforts to dilute the shares of the
     minority  shareholders of SCII. For the purposes of this clause, shares are
     diluted only where such efforts result in the reduction of the value of the
     minority  shareholders' stock. It is understood that shares are not diluted
     due  to  stock  issued  in  the  course  of the anticipated three rounds of
     financing.

     m.  Professional  Services.

                                        4
<PAGE>
          i. Investor Relations Firm. The current management of SCTI will assist
     the  new management of PUBCO to retain an investor relations firm to create
     awareness  of  SCII  and  Histostem  on  a  worldwide  basis.

          ii.  Investment  Banker.  Both  Parties  hereby agree to interview and
     select  the best offer of a U.S. based investment banker to raise funds for
     PUBCO  as  set  forth  in  this  Agreement.

          iii. Legal Services for Histostem. The Law firm of Epstein, Becker and
     Green  may  be considered to serve as the Legal Advisor to Histostem during
     the  MOU  and  Definitive  Agreement  is  process,  upon  necessary.

     3. No Shop Clause . Upon execution of this MOU until the date of closing of
the  Definitive  Agreement,  Histostem  will  keep  the  terms of this agreement
confidential,  will  not  "shop"  or  otherwise  seek  more favorable terms from
another  investment  source,  and  will not to enter into any agreement with any
other  party  that  would  in any way prejudice the rights of SCTI. Both parties
agree to negotiate in Good Faith until the Definitive Agreement is completed and
executed.

     4.  Confidentiality.  Except  as required by applicable law, no information
regarding  this  MOU or any other agreement, or verbal or written communications
regarding  these Parties and the transaction described herein, shall be released
to the public or anyone outside of the respective companies' Boards of Directors
or  other professionals without the written consent of both Parties. The Parties
may  by  mutual  agreement  decide  to  issue a worldwide press release upon the
signing  of  this  MOU.  It  is understood that upon execution of the Definitive
Agreement,  SCTI  will  be  required  to  publicly  disclose  the  terms  of the
Definitive  Agreement on Form 8-K, and SCTI will issue a public press release at
that  time.

     5.  Binding  of  Successors.  This Agreement shall be binding on, and shall
inure  to  the  benefit  of,  the  parties  and  their  respective  heirs, legal
representatives,  successors  and  assigns.

     6.  Severability. Each provision of this MOU shall be treated as a separate
and independent clause. If any court of law should rule that a clause is illegal
or otherwise unenforceable, such clause shall be deleted from this MOU, and this
MOU  shall  be deemed to consist of the remaining clauses with the unenforceable
clause(s) stricken. Moreover, if one or more of the provisions contained in this
Agreement  should  for  any  reason be held to be excessively broad as to scope,
activity,  or  subject  so  as  to  be  unenforceable  at law, such provision or
provisions  shall  be construed by the appropriate judicial body by limiting and
reducing  it  or  them, so as to be enforceable to the maximum extent compatible
with  the  current  applicable  law.

     7.  Amendment of the MOU. This MOU may not be amended or modified except by
a  writing  executed  by  both  parties.

     8. Waiver. Any waiver by any Party of a breach of any provision of this MOU
shall  not  operate or be construed as a waiver of any subsequent breach of such
provision  or

                                        5
<PAGE>
any other provision hereof.

     9.  Entire  Agreement.  This MOU represents the entire understanding of the
parties  regarding  the terms and conditions hereunder, and supersedes all prior
communications, agreements and understandings, whether oral or written, relating
to  the  subject  matter  hereof.

     10.  Notices.  All  notices  and other communications hereunder shall be in
writing  and  shall  be  deemed  to  have  been  given  (i) on the date they are
delivered  if  delivered  in  person;  (ii)  on  the  date initially received if
delivered  by  facsimile  transmission  followed by registered or certified mail
confirmation;  (iii)  on  the date delivered by an overnight courier service; or
(iv)  on  the  third  business day after it is mailed by registered or certified
mail,  return  receipt  requested  with  postage  and other fees prepaid, to the
addresses  provided  by  each  party  to  the  other  parties.

     11.  Counterparts.  This  Agreement  may  be  executed  in  one  or  more
counterparts,  each  of  which  shall  be  deemed  an original, but all of which
together shall constitute one and the same instrument. Confirmation of execution
by  electronic  transmission of a facsimile signature page shall be binding upon
any  party  so  confirming.

     IN  WITNESS  WHEREOF, the Parties have executed this Agreement effective as
of  the  date  first  above  shown.

HISTOSTEM CO, LTD          STEM CELL THERAPY INT'L, INC

\s\ Dr. Hoon Han           \s\ Calvin Cao
----------------           --------------
By: Dr. Hoon Han           By: Calvin Cao
Title: CEO/President       Title: CEO/President
Dated: 2/22/06             Dated: 2/22/06

Witness: \s\Brian Lee, 2/22/8
         --------------------
By:  Brian Lee
Title:  Advisor to Histostem

                                        6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}]]